EPO-TRAUMA Trial

ErythroPOietin alfa to prevent mortality and reduce severe disability in critically ill TRAUMA patients: a multi-centre, stratified, double-blind, randomised, placebo-controlled trial. (The EPO-TRAUMA trial)

ErythroPOietin alfa to prevent mortality and reduce severe disability in critically ill TRAUMA patients

Sites36
Patients933

Committee
Contacts
Progress

Study Progress

Country	Recruited
Australia	506
New Zealand	179
Finland	89
Switzerland	59
Saudi Arabia	47
Ireland	31
Slovenia	12
Belgium	9
Germany	1
Total	933